Qualigen Therapeutics, Inc.
  • About Us
    • Our Company
    • Leadership
    • Why We Do It
    • Board of Directors
    • Careers at Qualigen
    • Contact Us
  • Therapeutics
    • Pipeline
    • AS1411
    • ALAN
    • ALAN-RE
    • ALAN-CE
    • RAS-F
    • STARS
    • Resource Literature
      • AS1411 Resource Literature
      • RAS Resource Literature
  • Diagnostics
    • FastPack® IP
  • Patients
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Customer Support
    • Ordering
    • Technical Support
    • SDS
    • OnQ Training

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 20, 2020 8:00am EDT

Qualigen Therapeutics Announces Issuance of STARS™ Technology Patent by the U.S. Patent and Trademark Office

Aug 14, 2020 5:24pm EDT

Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today

Aug 06, 2020 3:59pm EDT

Qualigen Therapeutics to Host Business Update Conference Call on August 18, 2020

Aug 04, 2020 4:05pm EDT

Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aug 02, 2020 5:32pm EDT

Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 30, 2020 8:00am EDT

Qualigen Therapeutics Begins Shipping FastPack® COVID-19 Antibody Test

Jul 22, 2020 8:00am EDT

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates

Jul 13, 2020 8:00am EDT

Qualigen Therapeutics CEO Issues Letter to Stockholders

Jul 10, 2020 4:05pm EDT

Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 08, 2020 5:19pm EDT

Qualigen Therapeutics, Inc. Announces $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Qualigen Therapeutics, Inc. (Nasdaq: QLGN)
2042 Corte del Nogal

Suite B

Carlsbad, CA 92011

©2021 Qualigen
  • About Us
    ▼
    • Our Company
    • Leadership
    • Board of Directors
    • Careers at Qualigen
    • Contact Us
  • Therapeutics
    ▼
    • Pipeline
    • AS1411
    • ALAN
    • ALAN-RE
    • ALAN-CE
    • RAS-F
    • STARS
    • Resource Literature
      ▼
      • AS1411 Resource Literature
      • RAS Resource Literature
  • Diagnostics
    ▼
    • FastPack® IP
  • Patients
    ▼
    • Clinical Trials
  • Investors
    ▼
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Customer Support
    ▼
    • Ordering
    • Technical Support
    • SDS
    • OnQ Training